Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies

Cardiovascular Diabetology
Miriam LongoKatherine Esposito

Abstract

The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.

References

Dec 14, 2018·Cardiovascular Diabetology·Andrei C SpositoJosé Francisco Kerr Saraiva
Jun 6, 2019·Cardiovascular Diabetology·Shehan N RanderiaEtheresia Pretorius
Jun 20, 2019·The Journal of Clinical Endocrinology and Metabolism·Faraaz Ali ShahBryan J McVerry
Mar 18, 2020·Lancet·Andrea Remuzzi, Giuseppe Remuzzi
Mar 25, 2020·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Hien LauTanja Khosrawipour
Apr 23, 2020·JAMA : the Journal of the American Medical Association·Safiya RichardsonTheodoros P Zanos
May 16, 2020·Diabetes Care·Antonio CerielloUNKNOWN Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group

❮ Previous
Next ❯

Citations

Dec 7, 2020·Cardiovascular Diabetology·Abdullah M AlguwaihesAnwar A Jammah
Jan 11, 2021·Clinical Obesity·Andrej BelančićMarija Troskot Dijan
Mar 6, 2021·Frontiers in Public Health·Jesús Chávez-ReyesBruno A Marichal-Cancino
May 9, 2021·Cardiovascular Diabetology·Nunzia D'OnofrioRaffaele Marfella
May 18, 2021·Therapeutic Advances in Infectious Disease·Andrew Peter KyazzeIrene Andia-Biraro
Jun 15, 2021·Frontiers in Cardiovascular Medicine·Hayder M Al-KuraishyGaber El-Saber Batiha
Aug 3, 2021·International Journal of General Medicine·Mohammed BadediHalimh Mosa
Aug 24, 2021·Expert Opinion on Drug Safety·Yajnavalka BanerjeeManfredi Rizzo
Oct 27, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Djordje S PopovicManfredi Rizzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.